Categories:
ANVISA approves pilot project for optimized quality review based on the REQ
On September 2, 2026, ANVISA’s Board of Directors approved, during its 16th Public Ordinary Me
Ler mais
Vita Participates: ANVISA Seminar on the New Regulatory Framework for Herbal Medicines
On August 28, Vita attended the seminar hosted by ANVISA in Brasília on the new regulatory requirem
Ler mais
ANVISA publishes IN 467/2026: List of qualified impurities and their respective limits in accordance with RDC No. 964, from February 20, 2025.
On August 26, 2026, ANVISA published Normative Instruction (IN) No. 467/2026, amending IN No. 258/20
Ler mais
ANVISA updates Q&A on relative bioavailability/bioequivalence studies (Resolution RDC No. 742/2022)
On August 24, 2026, ANVISA published the 6th edition of its Questions and Answers document on Resolu
Ler mais
ANVISA opens to contributions for the review of the regulatory framework for biological products
On August 20, 2026, Brazil’s Health Regulatory Agency (ANVISA) opened a technical contribution
Ler mais
ANVISA releases priority queues for GMP certification applications
Brazil’s Health Regulatory Agency (ANVISA) has begun publishing queues of Good Manufacturing P
Ler mais
ANVISA – new application form for GMP certification for advanced therapy medicinal products
On August 14, 2026, Brazil’s Health Regulatory Agency (ANVISA) released the new Good Manufactu
Ler mais
ANVISA updates guidance on Periodic Benefit-Risk Evaluation Reports (PBRER)
A new schedule for preparing Periodic Benefit-Risk Evaluation Reports (PBRER) took effect on August
Ler mais
Health surveillance: the network that follows every stage of Brazilians’ day
Established under Law No. 13,098/2015, Brazil’s National Health Surveillance Day is observed o
Ler mais
ANVISA – Questions & Answers on the Sanitary Authorization of Cannabis Products: RDC No. 1,015/2026
On July 20, 2026, ANVISA published the 1st edition of the Questions & Answers (Q&A) document
Ler mais
ANVISA updates the Active Ingredient Registration Panel (Painel de Princípios Ativos em Registro): expanded data, greater depth for regulatory intelligence
In its original format, the panel displayed three variables per entry: active ingredient, regulatory
Ler mais
Law No. 15,471/2026 – Ensceis: Brazil’s new legal framework for the Health Economic-Industrial Complex and its implications for the pharmaceutical sector
On July 20, 2026, Law No. 15,471/2026 was enacted, establishing the National Health Strategy for B
Ler mais